Hospital
Hurley Medical Center
Hurley Medical Center was paid $118.34M by Medicaid between Jan 2018 and Dec 2024, across 506 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoHURLEY MEDICAL CENTER
FLINT, MI 48503
FLINT, MI 48503
33aNPI1598717480assigned 05/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$118.34M
24GClaims3,436,409
24DCodes billed506
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#5 of 86
Median peer was paid$21.55M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ECKER, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 497,065 | $18.61M | |
| 2019 | 524,616 | $17.89M | |
| 2020 | 467,331 | $14.64M | |
| 2021 | 517,737 | $16.36M | |
| 2022 | 490,016 | $15.66M | |
| 2023 | 499,496 | $18.41M | |
| 2024incomplete | 440,148 | $16.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 68,020 | 62,294 | $24.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 119,419 | 111,284 | $14.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 86,960 | 81,253 | $13.94M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.5% | 185,471 | 153,623 | $8.93M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.8% | 4,331 | 4,318 | $5.70M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 59,203 | 53,803 | $4.50M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.6% | 1,202 | 1,201 | $3.08M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.5% | 47,336 | 35,126 | $3.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 59,377 | 49,330 | $2.78M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 57,739 | 15,072 | $1.94M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 24,239 | 20,570 | $1.87M |
| 59025 | Fetal non-stress test | 1.3% | 17,673 | 10,138 | $1.51M |
494 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 3,478 | $1.26M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 13,409 | $1.20M |
| G0378 | Hospital observation service, per hour | <1% | 33,891 | $1.12M |
| 80061 | Lipid panel | <1% | 11,057 | $1.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12,279 | $1.03M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28,169 | $995K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 15,000 | $977K |
| 58661 | <1% | 367 | $971K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 50,221 | $958K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 24,866 | $948K |
| 93458 | <1% | 802 | $863K | |
| 71045 | Radiologic examination, chest; single view | <1% | 32,114 | $846K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 7,219 | $807K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,647 | $754K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,225 | $671K |
| 93975 | <1% | 7,609 | $650K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 1,054 | $607K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,900 | $589K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,242 | $569K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 41,200 | $515K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 41,261 | $508K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,475 | $426K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,367 | $363K |
| 97162 | <1% | 7,549 | $342K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,882 | $331K |
| 47562 | <1% | 133 | $323K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16,384 | $316K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 698 | $285K |
| 82947 | <1% | 8,927 | $279K | |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | <1% | 3,032 | $275K |
| 76801 | <1% | 5,075 | $272K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 479 | $264K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13,620 | $264K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 20,436 | $257K |
| 95811 | <1% | 666 | $256K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,484 | $252K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,442 | $237K |
| 76830 | Ultrasound, transvaginal | <1% | 5,387 | $236K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,213 | $216K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 10,534 | $212K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,699 | $212K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,976 | $209K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,458 | $201K |
| 36415 | Collection of venous blood by venipuncture | <1% | 147,584 | $196K |
| 76825 | <1% | 742 | $194K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,821 | $192K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 733 | $185K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 2,548 | $182K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 35,444 | $179K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,796 | $176K |
| 95816 | <1% | 2,094 | $173K | |
| 97161 | <1% | 2,816 | $168K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,553 | $164K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 460 | $161K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,749 | $152K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,965 | $151K |
| 76770 | <1% | 3,414 | $146K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,781 | $135K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 315 | $132K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 10,841 | $132K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,383 | $129K |
| 36430 | <1% | 1,145 | $121K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,733 | $119K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,879 | $111K |
| 86780 | <1% | 14,665 | $111K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 7,525 | $107K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17,614 | $105K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,289 | $102K |
| 86900 | <1% | 24,570 | $99K | |
| 73610 | <1% | 7,260 | $99K | |
| 94060 | <1% | 678 | $98K | |
| 10060 | <1% | 1,474 | $98K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,087 | $93K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,653 | $88K |
| 73130 | <1% | 7,128 | $86K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,031 | $85K |
| 93971 | <1% | 2,471 | $85K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,620 | $77K |
| 96367 | <1% | 3,631 | $75K | |
| 73562 | <1% | 6,948 | $74K | |
| 97166 | <1% | 1,745 | $73K | |
| 76818 | <1% | 1,297 | $72K | |
| 73630 | <1% | 6,253 | $72K | |
| 74018 | <1% | 6,042 | $72K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 945 | $68K |
| 93798 | <1% | 1,205 | $66K | |
| 93970 | <1% | 1,120 | $66K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,428 | $66K |
| 92523 | <1% | 747 | $64K | |
| 70491 | <1% | 1,006 | $64K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 613 | $62K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25,597 | $61K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 58,771 | $58K |
| 74174 | <1% | 774 | $57K | |
| 73140 | <1% | 2,829 | $55K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 108,067 | $55K |
| 87081 | <1% | 29,283 | $53K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,482 | $53K |
| 16020 | <1% | 2,076 | $53K | |
| 80053 | Comprehensive metabolic panel | <1% | 43,478 | $53K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,009 | $51K |
| 10061 | <1% | 471 | $51K | |
| 73110 | <1% | 5,063 | $50K | |
| 73523 | <1% | 1,303 | $49K | |
| 73030 | <1% | 5,603 | $49K | |
| 87210 | <1% | 31,721 | $48K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,663 | $48K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 366 | $47K |
| 70486 | <1% | 3,116 | $46K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,108 | $44K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,101 | $38K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,120 | $36K |
| 84702 | <1% | 20,392 | $36K | |
| 25605 | <1% | 52 | $35K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 6,119 | $35K |
| 64721 | <1% | 62 | $34K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 1,333 | $34K |
| 70496 | <1% | 1,267 | $31K | |
| 86762 | <1% | 6,403 | $31K | |
| 85027 | <1% | 40,894 | $30K | |
| 72131 | <1% | 2,077 | $29K | |
| 73080 | <1% | 3,418 | $28K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 151 | $28K |
| 87536 | <1% | 799 | $28K | |
| 96376 | <1% | 25,137 | $26K | |
| 72100 | <1% | 968 | $25K | |
| 86850 | <1% | 24,148 | $25K | |
| 97014 | <1% | 3,159 | $24K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 135 | $24K |
| 82951 | <1% | 4,045 | $24K | |
| 72141 | <1% | 273 | $23K | |
| 87340 | <1% | 8,326 | $23K | |
| 97022 | <1% | 4,069 | $23K | |
| 73502 | <1% | 2,563 | $22K | |
| 73590 | <1% | 3,681 | $22K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 88,430 | $21K |
| 73090 | <1% | 3,746 | $21K | |
| 72110 | <1% | 1,741 | $21K | |
| 87529 | <1% | 963 | $21K | |
| 76536 | <1% | 978 | $19K | |
| 83020 | <1% | 4,652 | $18K | |
| 88307 | <1% | 1,201 | $17K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 253 | $17K |
| 96415 | <1% | 396 | $17K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,272 | $17K |
| 84439 | <1% | 7,191 | $16K | |
| 87088 | <1% | 7,784 | $16K | |
| 70487 | <1% | 336 | $16K | |
| 97116 | <1% | 2,156 | $16K | |
| 83655 | <1% | 4,190 | $16K | |
| 93308 | <1% | 238 | $15K | |
| 86141 | <1% | 9,152 | $15K | |
| 87186 | <1% | 8,054 | $15K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,151 | $14K |
| 86803 | <1% | 2,811 | $14K | |
| 82728 | <1% | 3,775 | $14K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 332 | $13K |
| 83001 | <1% | 2,152 | $13K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 26 | $13K |
| 86360 | <1% | 679 | $13K | |
| 72070 | <1% | 839 | $13K | |
| 70498 | <1% | 1,610 | $12K | |
| 73700 | <1% | 354 | $12K | |
| 83002 | <1% | 2,060 | $12K | |
| 82670 | <1% | 1,304 | $12K | |
| 94375 | <1% | 823 | $12K | |
| 81001 | <1% | 35,693 | $12K | |
| 96112 | <1% | 103 | $12K | |
| 95782 | <1% | 27 | $11K | |
| 82570 | <1% | 8,034 | $11K | |
| 87400 | <1% | 6,336 | $11K | |
| L3670 | Shoulder orthosis, acromio/clavicular (canvas and webbing type), prefabricated, off-the-shelf | <1% | 1,228 | $11K |
| 72128 | <1% | 1,550 | $11K | |
| 84403 | <1% | 1,234 | $10K | |
| 12011 | <1% | 1,727 | $10K | |
| 73560 | <1% | 1,205 | $10K | |
| 80074 | <1% | 1,312 | $10K | |
| 76870 | <1% | 1,448 | $10K | |
| 90686 | <1% | 724 | $10K | |
| 12001 | <1% | 1,954 | $9K | |
| 86355 | <1% | 550 | $9K | |
| 86359 | <1% | 550 | $9K | |
| 86357 | <1% | 550 | $9K | |
| 88342 | <1% | 2,237 | $9K | |
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) | <1% | 270 | $9K |
| 29515 | <1% | 190 | $9K | |
| 83516 | <1% | 688 | $9K | |
| 71250 | <1% | 243 | $8K | |
| 74021 | <1% | 1,137 | $8K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 816 | $8K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 6,342 | $8K |
| 86901 | <1% | 24,509 | $8K | |
| 80076 | <1% | 23,533 | $8K | |
| 83970 | <1% | 522 | $7K | |
| 73060 | <1% | 1,563 | $7K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 233 | $7K |
| 87077 | <1% | 3,503 | $6K | |
| 97163 | <1% | 179 | $6K | |
| 83550 | <1% | 2,823 | $6K | |
| 97165 | <1% | 168 | $6K | |
| 87070 | <1% | 4,807 | $6K | |
| 71271 | <1% | 129 | $6K | |
| 73620 | <1% | 368 | $6K | |
| 82784 | <1% | 1,721 | $6K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 63 | $6K |
| 82607 | <1% | 2,221 | $6K | |
| 88304 | <1% | 4,663 | $6K | |
| 73660 | <1% | 249 | $6K | |
| 73120 | <1% | 397 | $6K | |
| 84100 | <1% | 76,547 | $5K | |
| 88142 | <1% | 393 | $5K | |
| 84156 | <1% | 5,446 | $5K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 30 | $5K |
| 74019 | <1% | 346 | $5K | |
| 81003 | <1% | 20,562 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 897 | $5K |
| 83540 | <1% | 3,014 | $5K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 14 | $5K |
| 85610 | <1% | 26,645 | $5K | |
| 82043 | <1% | 3,016 | $5K | |
| 86258 | <1% | 686 | $5K | |
| 86364 | <1% | 707 | $5K | |
| 83735 | <1% | 79,419 | $5K | |
| 84146 | <1% | 808 | $4K | |
| 73552 | <1% | 1,549 | $4K | |
| 84681 | <1% | 821 | $4K | |
| 94762 | <1% | 687 | $4K | |
| 85730 | <1% | 24,807 | $4K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 52 | $4K |
| 73070 | <1% | 556 | $4K | |
| 83525 | <1% | 1,143 | $4K | |
| 82247 | <1% | 2,624 | $3K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 6,216 | $3K |
| 86376 | <1% | 1,162 | $3K | |
| 64400 | <1% | 26 | $3K | |
| 71100 | <1% | 278 | $3K | |
| 82948 | <1% | 6,076 | $3K | |
| 82533 | <1% | 731 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 592 | $3K |
| 96116 | <1% | 51 | $3K | |
| 87205 | <1% | 4,940 | $3K | |
| 87486 | <1% | 6,132 | $3K | |
| 12032 | <1% | 27 | $3K | |
| 87581 | <1% | 6,135 | $3K | |
| 94799 | <1% | 4,638 | $3K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,810 | $3K |
| 83880 | <1% | 5,788 | $3K | |
| 76882 | <1% | 319 | $3K | |
| 99495 | <1% | 39 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 167 | $3K |
| 85652 | <1% | 6,468 | $3K | |
| 82248 | <1% | 2,877 | $2K | |
| 85045 | <1% | 3,238 | $2K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 222 | $2K |
| 84460 | <1% | 2,047 | $2K | |
| 85014 | <1% | 6,298 | $2K | |
| 82565 | <1% | 3,100 | $2K | |
| 82746 | <1% | 724 | $2K | |
| 82024 | <1% | 193 | $2K | |
| 85018 | <1% | 6,559 | $2K | |
| 72040 | <1% | 124 | $2K | |
| 84450 | <1% | 1,981 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 86 | $2K |
| 86480 | <1% | 96 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 192 | $2K |
| 72170 | <1% | 1,481 | $2K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 39 | $2K |
| 64999 | <1% | 13 | $2K | |
| 87184 | <1% | 566 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 16 | $2K |
| 99496 | <1% | 24 | $2K | |
| 84550 | <1% | 1,529 | $2K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 27 | $2K |
| 81015 | <1% | 2,725 | $2K | |
| C1769 | Guide wire | <1% | 2,152 | $2K |
| 97597 | <1% | 20 | $1K | |
| 16025 | <1% | 16 | $1K | |
| 82677 | <1% | 173 | $1K | |
| 87075 | <1% | 1,623 | $1K | |
| 12002 | <1% | 1,139 | $1K | |
| 87147 | <1% | 314 | $1K | |
| 82550 | <1% | 3,839 | $1K | |
| 83690 | <1% | 29,707 | $1K | |
| 86706 | <1% | 405 | $1K | |
| 84480 | <1% | 223 | $1K | |
| 82105 | <1% | 361 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 329 | $1K |
| 76820 | <1% | 4,006 | $1K | |
| 82310 | <1% | 1,719 | $1K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 18 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,329 | $1K |
| 80051 | <1% | 3,354 | $1K | |
| 72052 | <1% | 43 | $1K | |
| 81025 | <1% | 34,005 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,448 | $963.08 |
| 88341 | <1% | 27 | $945.37 | |
| 87420 | <1% | 1,178 | $934.02 | |
| 86336 | <1% | 173 | $913.19 | |
| 87641 | <1% | 211 | $884.92 | |
| 84402 | <1% | 90 | $857.43 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 45,099 | $850.72 |
| 87631 | <1% | 1,995 | $840.34 | |
| 96111 | <1% | 12 | $832.68 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,453 | $799.78 |
| 85049 | <1% | 966 | $729.19 | |
| 84520 | <1% | 2,073 | $677.47 | |
| 99152 | <1% | 2,743 | $669.00 | |
| 93017 | <1% | 504 | $628.01 | |
| 82150 | <1% | 4,711 | $602.38 | |
| 86870 | <1% | 14 | $602.22 | |
| 73200 | <1% | 27 | $587.77 | |
| 86696 | <1% | 97 | $584.37 | |
| 97035 | <1% | 134 | $577.90 | |
| 83615 | <1% | 607 | $567.54 | |
| 87505 | <1% | 25 | $531.19 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 42 | $516.00 |
| 29125 | <1% | 319 | $505.26 | |
| 80164 | <1% | 1,888 | $469.45 | |
| 88302 | <1% | 1,156 | $465.78 | |
| 73600 | <1% | 40 | $453.97 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 50 | $431.55 |
| 97602 | <1% | 271 | $421.09 | |
| 86038 | <1% | 118 | $414.37 | |
| 73522 | <1% | 15 | $407.82 | |
| 86695 | <1% | 97 | $398.21 | |
| 87640 | <1% | 38 | $396.24 | |
| 87040 | <1% | 3,094 | $372.74 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 2,253 | $369.75 |
| 82330 | <1% | 1,668 | $360.61 | |
| 84484 | <1% | 24,012 | $355.35 | |
| 84481 | <1% | 55 | $353.27 | |
| 76857 | <1% | 13 | $349.56 | |
| 73100 | <1% | 48 | $327.21 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 25,097 | $320.21 |
| 82627 | <1% | 44 | $307.05 | |
| 82010 | <1% | 3,204 | $295.51 | |
| 86592 | <1% | 132 | $295.32 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,121 | $278.20 |
| 86645 | <1% | 56 | $275.75 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,156 | $275.65 |
| 86705 | <1% | 34 | $272.41 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 29,377 | $270.31 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 15,421 | $270.07 |
| 94150 | <1% | 1,042 | $270.00 | |
| 89050 | <1% | 446 | $269.86 | |
| 87449 | <1% | 496 | $267.41 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 54 | $242.75 |
| 86644 | <1% | 56 | $235.44 | |
| 85379 | <1% | 4,661 | $223.35 | |
| 96127 | <1% | 484 | $210.56 | |
| 82077 | <1% | 11,716 | $209.84 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,923 | $201.45 |
| 86694 | <1% | 30 | $188.43 | |
| 82803 | <1% | 6,528 | $184.84 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 5,178 | $177.49 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 7,473 | $174.93 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,208 | $174.55 |
| 80069 | <1% | 305 | $173.02 | |
| 86778 | <1% | 31 | $170.54 | |
| 86777 | <1% | 31 | $170.32 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 2,300 | $157.46 |
| J2704 | Injection, propofol, 10 mg | <1% | 26,270 | $157.44 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,681 | $146.69 |
| 70360 | <1% | 38 | $144.02 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,305 | $138.98 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 912 | $135.98 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 18,080 | $135.21 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,199 | $135.00 |
| 83605 | <1% | 7,468 | $134.90 | |
| 83986 | <1% | 218 | $134.81 | |
| 84075 | <1% | 516 | $132.34 | |
| 81002 | <1% | 12,809 | $130.15 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,517 | $129.00 |
| 84132 | <1% | 214 | $114.61 | |
| 83498 | <1% | 15 | $107.59 | |
| 90715 | <1% | 6,183 | $104.96 | |
| 84436 | <1% | 25 | $104.14 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,530 | $101.20 |
| 86800 | <1% | 116 | $98.06 | |
| 94660 | <1% | 111 | $97.14 | |
| 76010 | <1% | 15 | $96.28 | |
| 76642 | <1% | 12 | $94.86 | |
| 85246 | <1% | 13 | $86.74 | |
| 97012 | <1% | 23 | $85.40 | |
| 84145 | <1% | 955 | $83.83 | |
| 76827 | <1% | 557 | $79.62 | |
| 82800 | <1% | 2,443 | $77.48 | |
| 85007 | <1% | 308 | $76.83 | |
| 80047 | <1% | 947 | $70.75 | |
| 85240 | <1% | 13 | $69.55 | |
| 86308 | <1% | 205 | $65.80 | |
| 84157 | <1% | 118 | $64.87 | |
| 86431 | <1% | 27 | $62.76 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 2,574 | $62.01 |
| 86708 | <1% | 26 | $61.25 | |
| 84155 | <1% | 486 | $60.45 | |
| 85384 | <1% | 25 | $59.02 | |
| 82140 | <1% | 514 | $48.34 | |
| 82977 | <1% | 12 | $45.30 | |
| 82945 | <1% | 87 | $41.65 | |
| 80143 | <1% | 2,859 | $41.32 | |
| 84466 | <1% | 12 | $39.44 | |
| 85660 | <1% | 13 | $38.06 | |
| 82950 | <1% | 14 | $36.71 | |
| 82040 | <1% | 162 | $27.90 | |
| 87328 | <1% | 12 | $26.31 | |
| 80202 | <1% | 35 | $20.66 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 45,145 | $20.52 |
| 76821 | <1% | 1,582 | $20.10 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 2,642 | $20.03 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,705 | $17.23 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 14 | $16.44 |
| 86039 | <1% | 12 | $16.31 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,859 | $15.51 |
| 87324 | <1% | 12 | $15.06 | |
| 87076 | <1% | 12 | $10.64 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 20 | $8.76 |
| J3490 | Unclassified drugs | <1% | 1,130 | $6.76 |
| 86905 | <1% | 12 | $5.44 | |
| 80179 | <1% | 2,704 | $4.75 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 24,238 | $4.39 |
| 82272 | <1% | 958 | $3.58 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,963 | $2.88 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 25 | $2.84 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 101 | $1.14 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 6,959 | $0.37 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,355 | $0.31 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,396 | $0.23 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,149 | $0.23 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 2,030 | $0.20 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 13,459 | $0.05 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,674 | $0.02 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 357 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 166 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 283 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 1,505 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 745 | $0.00 |
| 96368 | 0% | 61 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 836 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 1,527 | $0.00 |
| 97010 | 0% | 6,128 | $0.00 | |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 371 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 177 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 249 | $0.00 |
| 93320 | 0% | 724 | $0.00 | |
| 12013 | 0% | 70 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 181 | $0.00 |
| A9270 | Non-covered item or service | 0% | 201 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 16 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 13 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 96 | $0.00 |
| J2280 | Injection, moxifloxacin, 100 mg | 0% | 29 | $0.00 |
| 64402 | 0% | 29 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 25 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 33 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 399 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 30 | $0.00 |
| 29130 | 0% | 19 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 16 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 15 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 2,821 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 2,212 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 179 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 963 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 4,026 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 198 | $0.00 |
| 76376 | 0% | 90 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 777 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 919 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 308 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 258 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 1,989 | $0.00 |
| 93325 | 0% | 2,434 | $0.00 | |
| 51702 | 0% | 40 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 315 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 617 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 252 | $0.00 |
| 85396 | 0% | 234 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 21 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 160 | $0.00 |
| A4628 | Oral and/or oropharyngeal suction catheter, each | 0% | 95 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 18 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 43 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 235 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 53 | $0.00 |
| L0140 | Cervical, semi-rigid, adjustable (plastic collar) | 0% | 30 | $0.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 47 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 50 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 135 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 258 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 68 | $0.00 |
| 76813 | 0% | 16 | $0.00 | |
| 73000 | 0% | 17 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 79 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialECKER, KIMBERLY (DIRECTOR OF PROFESSIONAL BILLING)
| Provider | Location | Paid |
|---|---|---|
| Hurley Medical Center | Flint, MI | $18.81M |
| Hurley Medical Center | Flint, MI | $8.43M |
| Hurley Medical Center | Flint, MI | $7.75M |
| Hurley Medical Center | Flint, MI | $5.00M |
| Hurley Medical Center | Flint, MI | $4.69M |
| Hurley Medical Center | Flint, MI | $3.71M |
| Hurley Medical Center | Flint, MI | $2.75M |
| Hurley Medical Center | Flint, MI | $2.67M |
| Hurley Medical Center | Flint, MI | $2.36M |
| Hurley Medical Center | Burton, MI | $1.43M |
| Hurley Medical Center | Flint, MI | $1.29M |
| Hurley Medical Center | Flint, MI | $1.11M |
| Hurley Medical Center | Flint, MI | $700K |
| Hurley Medical Center | Durand, MI | $562K |
| Hurley Medical Center | Flint, MI | $543K |
| Hurley Medical Center | Flint, MI | $475K |
| Hurley Medical Center | Flint, MI | $380K |
| Hurley Medical Center | Flint, MI | $356K |
| Hurley Medical Center | Flint, MI | $48K |
| Hurley Medical Center | Flint, MI | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.